Dec 22, 2005 by Karl ThielThe Skinny on Obesity DrugsDrug companies are working on novel new ways to battle the bulge. Which pharmas' efforts might fatten your portfolio?
Oct 26, 2005 by Karl ThielStake Out Your StocksIf you're thinking of selling, sometimes it pays to watch and wait.
Aug 30, 2005 by Karl ThielA Blueprint to Biotech ProfitsThree keys to identifying promising biotech companies before the rest of the market.
Aug 16, 2005 by Karl ThielNew Life for Boston Life Sciences?The biotech's stock soars on news of potential approval of its imaging agent for Parkinson's and ADHD.
Jul 26, 2005 by Karl ThielIs Archipelago on Fantasy Island?Archipelago's getting bought out, but has its stock risen too high?
Jul 22, 2005 by Karl ThielCancer Drug: A Shot at SuccessIs the world finally ready for cancer vaccines?
Jul 20, 2005 by Karl ThielPride and PreclinicalsArQule has surged, but take its early-stage data with a grain of salt.
Jul 18, 2005 by Karl ThielStocks That Make You Breathe EasierAllergies and asthma are big markets that several firms aim to tackle.
Jun 29, 2005 by Karl ThielCash In on the Future of ScienceWith some diligence, you can ride your high school biology to biotech investing success.
Jun 16, 2005 by Karl ThielBiDil's Bid for a Narrow LabelToday's FDA panel could bring good news to NitroMed. The company hopes it's not too good.
May 31, 2005 by Karl ThielIs Eyetech Better Than It Looks?There may be some life in this one-trick pony after all.
May 25, 2005 by Karl ThielA Gold Mine in GenericsWill NitroMed's new math add up to investment success?
May 13, 2005 by Karl ThielBoning Up on New DrugsAre new osteoporosis therapies compelling investments, or is the field too crowded?
Apr 4, 2005 by Karl ThielCV Therapeutics' Great ResumeWith biotechs in the doldrums, this Fool goes hunting.
Mar 30, 2005 by Karl ThielWho's Behind Naked Shorting?In search of culprits in the practice of illegal short selling.
Feb 24, 2005 by Karl ThielReally, It's Not SpywareViewpoint claims to be offering spyware that's not.
Feb 17, 2005 by Karl ThielSleeping on Neurocrine's SharesWhy haven't these shares moved? It's partly history, with delays in getting an insomnia drug to market.
Feb 10, 2005 by Karl ThielThe Worst Has Happened. Time to Sell?Biotech stocks can be volatile, but dumping them in response to bad news isn't always the smartest option.
